- Home
- HROW
HROW
Harrow Inc.
as 05-09-2025 4:00pm EST
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | NASHVILLE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $58.40 | AVG Volume (30 days): | 411.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.08 - $59.23 | Next Earning Date: | 05-08-2025 |
| Revenue: | $212,858,000 | Revenue Growth: | 53.49% |
| Revenue Growth (this year): | 44.71% | Revenue Growth (next year): | 36.66% |
Latest Harrow Inc. News
HROW Breaking Stock News: Dive into HROW Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Harrow Announces First-Quarter 2025 Financial Results
GuruFocus.com
2 days ago
Harrow Inc (HROW) Q1 2025 Earnings Report Preview: What to Look For
GuruFocus.com
3 days ago
What To Expect From Harrow Inc (HROW) Q1 2025 Earnings
Business Wire
5 days ago
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025
Simply Wall St.
12 days ago
3 Growth Stocks Insiders Are Betting On
PR Newswire
16 days ago
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
GuruFocus.com
18 days ago
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Business Wire
a month ago
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
Compare HROW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HROW Harrow Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.